Evidence map›Paper›PMID 41425286›Full record

ReviewFrontiers in digital health2025

Using shared clinical decision support to reduce adverse drug events and improve patient safety.

Jiancheng Ye, Sophie Bronstein

Abstract readReview
In one paragraph

Review in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Digital health technology burden and frustration among patients with multimorbidity.Journal of the American Medical Informatics Association : JAMIA · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jiancheng YeWeill Cornell Medicine, Cornell University, New York, NY, United States.
Sophie BronsteinWeill Cornell Medicine, Cornell University, New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Medications, while essential therapeutic tools in modern healthcare, carry the inherent risk of causing adverse drug events (ADEs) that can result in significant morbidity, mortality, and healthcare costs. Despite substantial research efforts in this domain, the majority of ADEs remain undetected due to reliance on voluntary reporting systems and inadequate surveillance mechanisms. Consequently, the true scope and impact of ADEs are likely far greater than currently recognized. Objective: To examine the role of shared clinical decision support (SCDS) in reducing adverse drug events and enhancing patient safety outcomes through systematic integration of clinical decision support systems with shared decision-making frameworks. Methods: We conducted a narrative review of literature published up to June 2025, utilizing validated patient safety frameworks to identify contextual factors, systemic challenges, and evidence-based strategies that influence adverse drug event occurrence and prevention. Results: Multiple interconnected factors contribute to ADE susceptibility, including healthcare provider competencies (inadequate monitoring, symptom recognition failures), clinical environment characteristics (technology workarounds, equipment complexity), pharmacy system factors (high-risk medication storage, limited pharmacist involvement), and patient-specific variables (polypharmacy, multimorbidity, age-related physiological changes). Critical risk determinants include provider fatigue and burnout, inadequate monitoring protocols, medication administration errors, and systemic communication failures. Successful implementations require multifaceted approaches integrating health information technology components, stakeholder engagement, customized clinical decision rules, and continuous quality improvement processes. Conclusions: Shared clinical decision support represents a paradigm shift toward patient empowerment, enabling active patient participation in healthcare decisions while leveraging technology-enhanced clinical guidance. The most promising approach to ADE elimination involves a comprehensive integration of educational initiatives, human factors engineering, robust shared clinical decision support systems, and multidisciplinary collaborative care models.

Indexed as

adverse drug eventsclinical decision supportdigital health serviceshealth information technologyhuman factorspatient safetyrisk assessmentshared decision-making

Identifiers

PMID41425286
PMCPMC12711735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.